CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor

Immune checkpoint inhibitors (ICIs) have shown clinical benefit in solid tumors, with modest rates of clinical response. Hence, improved therapeutic approaches need to be investigated. Herein, we assessed a combination of chidamide plus celecoxib (called CC-01) combined with programmed cell death pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jia-Shiong, Chou, Cheng-Han, Wu, Yi-Hong, Yang, Mu-Hsuan, Chu, Sz-Hao, Chao, Ye-Su, Chen, Chia-Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776878/
https://www.ncbi.nlm.nih.gov/pubmed/35058524
http://dx.doi.org/10.1038/s41598-022-05055-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776878/
https://www.ncbi.nlm.nih.gov/pubmed/35058524
http://dx.doi.org/10.1038/s41598-022-05055-8

Ejemplares similares